ACE-536 has the potential to produce a significant influence on the treatment of anemia in MDS, stated Matthew Sherman, M.D., Chief Medical Officer of Acceleron. Unlike erythropoietin, ACE-536 may target the specific defect in the erythropoietic maturation procedure in MDS sufferers and we are optimistic that it could become a significant new therapeutic option for this underserved patient population. .. Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for tumor and orphan diseases, announced the initiation of a phase 2 study of it is investigational protein therapeutic today, ACE-536, to take care of anemia in individuals with myelodysplastic syndromes .The initial ART regimens had been zidovudine, lamivudine, and efavirenz in 80 percent of participants; stavudine, lamivudine, and efavirenz in 19 percent; and tenofovir, lamivudine, and efavirenz in 1 percent. Switches to another ART regimen happened in 46 percent of participants ; in 52 individuals, the switch was to tenofovir. Participants receiving stavudine were systematically switched to tenofovir at 12 weeks initially. Primary End Point The proportion of participants who died by 26 weeks was greater in the earlier-ART group than in the deferred-ART group . The difference in mortality between the two groups occurred early during treatment, during study days 8 through 30 , when individuals were getting consolidation fluconazole therapy .